Where do we stand with IPF treatment?
Despite receiving ‘weak no’ recommendations in the updated guidelines on treating patients with Idiopathic Pulmonary Fibrosis (IPF), two key treatment options are pirfenidone and N-acetylcysteine (NAC), and both are used in clinical practice. The efficacy of pirfenidone is supported by a number of P...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643087/ |